Business News

Roche gets Phase 3 trial waiver for higher dose of multiple sclerosis drug

FinSiddhi

CDSCO expert panel grants waiver for 920 mg Ocrelizumab, subject to Roche conducting a Phase 4 clinical trial in the Indian population for proposed indications
Read more at the source

Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and credits belong to the original authors and publishers.

Related Posts

Will Paras Defence, MTAR Tech, HAL, other defence stocks deliver explosive returns? Here’s what analysts say

Defence stocks are currently soaring, largely fueled by progressive government reforms aimed at strengthening the sector. Analysts maintain a positive outlook on future growth, bolstered by the Defence Ministry’s list that encourages domestic procurement. Although valuations may seem elevated, market corrections present prime opportunities for investors. As India aspires to lead in global defence technology,…

How to stop Vaibhav Sooryavanshi? Harbhajan Singh reveals the only way

Harbhajan Singh suggests bowlers must attack Vaibhav Sooryavanshi to succeed. He believes containing the young batter is not an effective strategy. Sooryavanshi’s aggressive style forces elite bowlers to reconsider their approach. The former spinner emphasises taking wickets over defensive bowling tactics. Accepting boundaries is part of the risk when facing this talented player.